FIELD: chemistry.
SUBSTANCE: invention relates to copolyether composition for manufacturing products for medical purposes, as well as to such product. Copolyether composition represents product of reaction of polycondensation polyester and at least one lactone. Polycondensation polyesther represents product of reaction of diglycolic acid and/or its derivative with diethyleneglycol and ethyleneglycol. Molar ratio of diethyleneglycol to ethyleneglycol is in the range from approximately 2:1 to 4:1. Copolyether composition contains from approximately 30 to 50 wt % of polycondensation polyether counted per the total copolyether weight and possesses degree of crystallinity in the range from approximately 10 to 50%.
EFFECT: obtaining hydrophilic polymer, characterised by low degree of crystallinity, glass transition temperature (Tg) much lower than room temperature, which can be especially useful in production of monofibres, multifilament fibres, microspheres, non-woven materials, obtained by aerodynamic melt spraying, or other products for medical purposes, requiring high rate of hydrolysis in combination with excellent mechanical properties.
19 cl, 1 tbl, 4 ex
